TY  - BOOK
AU  - Chaguturu,Rathnam
TI  - Collaborative innovation in drug discovery: strategies for public and private partnerships 
T2  - Wiley series on technologies for the pharmaceutical industry
SN  - 9781118778128 (ePub)
AV  - RM301.25 
U1  - 615.1/9 23
PY  - 2014///]
CY  - Hoboken, New Jersey
PB  - John Wiley & Sons Inc.
KW  - Drug Discovery
KW  - Public-Private Sector Partnerships
KW  - MEDICAL
KW  - Pharmacology
KW  - bisacsh
KW  - Drug development
KW  - fast
KW  - Public-private sector cooperation
KW  - Electronic books
N1  - Includes bibliographical references and index; Table of Contents; Wiley Series on Technologies for the Pharmaceutical Industry; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; General Principles for Success; Notes; 2: Divided We Fall; Challenges; Collaboration Models; Examples of Successful Biomedical CollaborationsPrinciples of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References; 4: The Changing Face of Innovation in Drug Discovery; Introduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug DiscoveryAn Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery; Future Perspectives: Where Is Innovation Leading?; References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public DomainEffective Management of Academia-Pharma Collaborations; Concluding Remarks; References; Notes; 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges; Evolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Funding for Collaborations with AcademiaNew Initiatives to Transform University-Industry Collaborations; Issues Affecting University-Industry Collaborations; Differences between Large- and Small-/Medium-Sized Companies; Large Companies Share Certain Characteristics; Small- and Medium-Sized Enterprises (SMEs) Offer a Contrasting Perspective; The National Academies' University-Industry Demonstration Partnership; Strategies for Building High-Value, High Return U-I Partnerships; Conclusion; Note on this Chapter; Note; References; gm
UR  - http://dx.doi.org/10.1002/9781118778166
ER  -